Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$192.1MMiss by $2.6M
EPS$1.01Beat by $0.19
Revenue estimate$194.7M
EPS estimate$0.82

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$205.3M
EPS estimate$0.42

Financials

Q3 2025

Income statement

See full
Revenue$192.1M+9.3%
Gross profit$173.1M+9.5%
Operating income-$60.2M-247%
Net income-$45.1M-217%
EPS (diluted)-$0.80-216%

Balance sheet

See full
Cash & equivalents$152.8M+382%
Total debt$42.2M+10.6%
Total equity$1.0B+4.2%
Total assets$1.4B+5.7%

Cash flow

See full
CapEx$129.0K-35.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.68B+56.3%
Enterprise value$2.57B+49.3%
P/S3.9×+1.3×

Profitability

See full
Gross margin88.6%-0.4pp
Operating margin-5.4%-14.5pp
Net margin-2.8%-12.0pp

Returns & leverage

See full
Return on equity-1.9%-8.1pp
Debt / equity0×0.0×
Current ratio1.8×-0.4×

Segments

By product

See full
Qelbree$81.4M+30.6%
GOCOVRI$40.8M+14.6%
Collaboration revenue (ZURZUVAE)$20.2M—
Oxtellar XR$12.0M-59.7%
APOKYN$10.4M-47.7%

By segment

See full
Reportable Segment$192.1M+9.3%

Versus estimates

Revenue

Q1 2026$207.7MBeat by $14.8MQ4 2025$211.6MBeat by $16.4M
Q3 2025$192.1MMiss by $2.6M
Q2 2025$165.5MMiss by $2.8MQ1 2025$149.8MBeat by $1.9MQ4 2024$174.2MBeat by $18.9M

Diluted EPS

Q1 2026$0.59Beat by $0.31Q4 2025$0.92Beat by $0.64
Q3 2025$1.01Beat by $0.19
Q2 2025$0.91Beat by $0.44Q1 2025$0.42Beat by $0.04Q4 2024$0.75Beat by $0.29

Ask the moment Supernus Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Supernus Pharmaceuticals report Q3 2025 earnings?
Supernus Pharmaceuticals (SUPN) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Supernus Pharmaceuticals's Q3 2025 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $192.1M and eps of $1.01 for Q3 2025.
Did Supernus Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $194.7M by $2.6M. EPS beat the consensus estimate of $0.82 by $0.19.
How did Supernus Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.3% from $175.7M a year earlier and eps declined 4.7% from $1.06.
Where can I find Supernus Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001356576-25-000068) and the 10-Q periodic report (0001356576-25-000071) directly on SEC EDGAR. The filing index links above go to sec.gov.